Lincoln Pharmaceuticals reports 28.33 per cent rise in standalone net profit in Q4 FY21

Company recommends dividend of 15 per cent – Rs 1.5 per share for FY21

Lincoln Pharmaceuticals has reported net profit of Rs 11.85 crores in Q4FY21 as against the net profit of Rs 9.23 crores in the corresponding period last year, growth of 28.33 per cent. The net revenue from operations in Q4FY21 was reported at Rs 77.54 crores, higher by 3.03 per cent over previous fiscal’s same period net revenue from operations of Rs 75.26 crores, as per a statement released by the company.

The company also reported an EBITDA of Rs 16.74 crores in Q4FY21, rise of 28.25 per cent as compared to Rs 13.05 crores in the corresponding period last year. Further, EPS for Q4FY21 was at Rs 5.92 per share as compared to Rs 4.62 in the corresponding period last year. The company has recommended a dividend of 15 per cent – Rs 1.50 per share on the face value of Rs 10 per share.

During the fiscal, promoter group of Lincoln Pharmaceuticals increased holding in the company to 37.25 per cent – a rise of 4.9 per cent (490 bps) from 32.36 per cent, as of 31st March, 2020. The promoter group bought 9.8 lakh shares from the secondary market during the year. Backed by improvement in the company’s financial risk profile, steady growth in scale and margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.

Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said, “Company’s performance during the quarter and full year has been quite robust, and considering that we have recommended a dividend of Rs 1.50 per share. The company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in coming years. Our strategic growth initiatives, product and geographical expansion and operational efficiency are likely to maximise value for all stakeholders in the near-to-medium term.”

The statement also mentioned that the company is witnessing good traction in the export business, which is expected to get further boost once the European Union (EU) operations begin. It plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products.

Lincoln Pharmaceuticals currently exports to over 60 countries and plans to expand to more than 90 countries. For the next phase of growth, the company is building a strong portfolio in lifestyle and chronic segment, especially dermatology, gastro and pain management to complement its strong presence in the acute segment.

EBITDAfinancial highlightsLincoln Pharmaceuticals
Comments (0)
Add Comment